InsiderPulse
← 10-K / 10-Q
10-QVVOS

Vivos Therapeutics, Inc.

Filed 2026-05-20Period ending 2026-03-31
EDGAR ↗All periods →

Income Statement

Line Item2026-03-31Q/QY/Y
Revenue$5.1M+70.5%
Gross Profit$3.1M+102.7%
SG&A Expense$9.0M+83.4%
Operating Income-$6.6M-68.8%
Interest Expense$1.1M
Pre-tax Income-$7.8M-100.6%
Net Income-$7.7M-98.8%
EPS (Basic)-$0.52-15.6%
EPS (Diluted)-$0.52-15.6%

Balance Sheet

Line Item2026-03-31Q/QY/Y
Cash & Equivalents$2.1M+4.0%-9.9%
Accounts Receivable$1.8M+11.9%+146.4%
Current Assets$4.8M+9.9%+33.6%
Total Assets$25.0M-0.4%+122.0%
Current Liabilities$17.9M-0.8%+281.6%
Long-term Debt$617K-18.1%
Total Liabilities$26.3M-1.5%+282.7%
Stockholders' Equity-$1.1M+23.6%-125.8%

Cash Flow

Line Item2026-03-31Q/QY/Y
Operating Cash Flow-$6.0M-58.3%
Capital Expenditures$18K-85.2%
Investing Cash Flow-$18K+85.2%
Financing Cash Flow$6.1M
Free Cash Flow-$6.0M-53.9%